Domain Therapeutics erhält 2 Mio. Euro von Seventure, SODIV, AIRFI, IP Growth, Auriga und Sam Eletr
- Domain Therapeutics closes 2 million Euros funding round
- The funds will enable the company to strengthen its position as a strategic collaborative partner to the pharmaceutical industry for discovering drugs targeting GPCRs
Domain Therapeutics, a biopharmaceutical company specialized in the research and early development of new drug candidates targeting GProtein Coupled Receptors (GPCRs), announces today that it has completed a two million Euros financing round.
Half of the funds have been provided by a new investor, Seventure Partners and the other half has been committed by another new investor, SODIV, and Domain’s existing shareholders – AIRFI, IP Growth, Auriga and Sam Eletr, the Chairman of the Board… vollständiger Artikel (pdf)